TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Icecure Medical ( (ICCM) ) has provided an announcement.
On November 18, 2025, IceCure Medical announced that its ProSense® Cryoablation System received regulatory approval from Swissmedic for treating breast, lung, liver, and kidney cancers in Switzerland. This approval enhances IceCure’s regulatory and commercial momentum, following the recent FDA marketing authorization for low-risk breast cancer in the U.S. The Swiss healthcare market, known for its innovation and high-quality care, offers significant potential for IceCure to expand the adoption of ProSense® as a standard-of-care alternative to surgery, further solidifying its position in the global medical technology industry.
The most recent analyst rating on (ICCM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Underperform.
Icecure Medical’s overall stock score is primarily impacted by its significant financial challenges, including declining revenues and substantial losses. Technical indicators also show weak momentum, further contributing to a low score. While there is potential regulatory progress with ProSense, financial difficulties and poor valuation metrics weigh heavily on the stock’s outlook.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, is a company specializing in advanced cryoablation therapy systems that utilize liquid nitrogen to destroy tumors, both benign and cancerous. The company’s primary focus areas include breast, kidney, bone, and lung cancer, offering a minimally invasive alternative to surgical tumor removal. Their flagship product, the ProSense® system, is marketed globally for various approved indications, including in the U.S., Europe, and Asia.
Average Trading Volume: 1,623,887
Technical Sentiment Signal: Sell
Current Market Cap: $48.96M
Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.